xmt-1536
mAbexperimentalADC
Clinical trial activity
4 trials · 3 clinical orgs · 0 marketing orgs
Phase 1
4
Phase 2
1
Phase 3
0
Phase 4
0
Earliest trial started Dec 12, 2017 (NCT06517433)
Timeline
2010s
- Jan 1, 2017
Earliest Phase 1 Sponsor(trial)
Indications
Mechanism of action
SLC34A2 inhibitor
Chemistry & pharmacology
- Inorganic
- No
- Polymer
- No
- Multi-specific
- No
- Payload
- Unclear
Oral
No
Parenteral
No
Topical
No
Sources
- ChEMBLCHEMBL4297851 ↗
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT04907968 | Phase 1/Phase 2 (Phase 2) | Jun 11, 2021 | IQVIA, Mersana Therapeutics |
| NCT06517485 | Phase 1 | Jul 30, 2019 | Mersana Therapeutics |
| NCT03319628 | Phase 1 | Dec 12, 2017 | Mersana Therapeutics, Novella Clinical |
| NCT06517433 | Phase 1 | Dec 12, 2017 | Mersana Therapeutics |
Showing 4 of 4 trials
Page 1 / 1
Organizations
Research & Development (3)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Mersana Therapeutics | For profit | 4 | 4 | 2 | 2017 |
| IQVIA | For profit | 1 | 0 | 1 | 2021 |
| Novella Clinical | For profit | 1 | 0 | 1 | 2017 |
3 organizations
Page 1 / 1